Santhera Pharms Hldgs Ltd (SPHDF) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, welcome to this Althera Pharmaceuticals half year 2024 financial results and corporate update conference call. I am George, the chorus call operator. I would like to remind you that all participants will be listened on remote and the conference is being recorded. The presentation will be followed by Q&A session. You can register for questions at any time by pressing star N1 on your telephone. For operator assistance, please press star N0. The conference must not be recorded for publication or broadcast. This conference call may contain certain forward-looking statements based on current assumptions and forecasts made by Santera Pharmaceuticals. Such statements involve certain risks, uncertainties, and other factors which could cause the actual result, financial condition, performance, or achievements of Santera Pharmaceuticals to be materially different from those expressed or implied by such statements. Those factors include those discussed in the Comprehensive Risk Factor Disclosure in the company's website at www.santerra.com. Santerra disclaims any obligation to update any forward logic statements. This conference may be downloaded on Santerra's website during the two weeks following the call. At this time, it's my pleasure to hand over to Mr. Dario Eklund, CEO. Please go ahead, sir. Thank you, George. Good afternoon and good morning to those following us in the U.S., and thanks for participating in today's conference call on the 2024 Half-Year Financial Results and Performance. I'm joined today by Andrew Smith, our CFO, and Dr. Shabir Hasham, who is our Chief Medical Officer. I'll start by sharing an overview of what Santera has achieved during the period, followed by the financial overview provided by Andrew. As always, you'll have the opp...